Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:PTCTNYSE:RDYNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$21.30+0.5%$19.84$17.24▼$28.96$13.65B1.041.13 million shs261,946 shsPTCTPTC Therapeutics$48.82+3.3%$46.80$28.72▼$58.38$3.87B0.52858,368 shs170,750 shsRDYDr. Reddy's Laboratories$14.73+1.1%$13.64$12.26▼$16.89$12.29B0.331.49 million shs644,857 shsSMMTSummit Therapeutics$26.55+1.9%$23.36$2.30▼$36.91$19.67B-0.943.82 million shs1.12 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S-0.42%+3.27%+2.71%-6.78%-24.35%PTCTPTC Therapeutics-1.21%+2.32%-4.98%-6.51%+29.64%RDYDr. Reddy's Laboratories-1.02%+1.71%+4.52%+12.80%+2.76%SMMTSummit Therapeutics+1.56%+2.48%+8.00%+40.83%+989.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.3701 of 5 stars3.33.00.00.02.80.03.1PTCTPTC Therapeutics3.9132 of 5 stars4.31.00.04.42.90.80.0RDYDr. Reddy's Laboratories1.9844 of 5 stars2.32.01.70.02.90.01.9SMMTSummit Therapeutics3.1916 of 5 stars4.53.00.00.03.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.1783.91% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$63.7530.58% UpsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0015.45% UpsideSMMTSummit Therapeutics 3.09Buy$37.4040.89% UpsideCurrent Analyst Ratings BreakdownLatest PTCT, SMMT, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B4.38$1.44 per share14.80$8.04 per share2.65PTCTPTC Therapeutics$1.77B2.18$2.35 per share20.80($10.85) per share-4.50RDYDr. Reddy's Laboratories$325.54B0.04$1.11 per share13.25$4.50 per share3.27SMMTSummit Therapeutics$700K28,162.96N/AN/A$0.11 per share241.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7612.2411.962.6536.30%16.78%13.79%8/14/2025 (Estimated)PTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/14/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6623.4517.96N/A17.25%17.87%12.32%7/25/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)Latest PTCT, SMMT, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.54%N/A12.12%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24PTCTPTC TherapeuticsN/A2.102.04RDYDr. Reddy's Laboratories0.021.921.38SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%PTCTPTC TherapeuticsN/ARDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%PTCTPTC Therapeutics5.50%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableRDYDr. Reddy's Laboratories24,800834.77 million818.05 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionablePTCT, SMMT, GMAB, and RDY HeadlinesRecent News About These CompaniesGF Fund Management CO. LTD. Purchases Shares of 16,905 Summit Therapeutics Inc. (NASDAQ:SMMT)May 27 at 5:14 AM | marketbeat.com25,000 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by Toronto Dominion BankMay 27 at 4:15 AM | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)May 27 at 3:38 AM | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Stock Holdings Increased by Bank of America Corp DEMay 27 at 3:15 AM | marketbeat.comDoes Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?May 26 at 11:01 AM | zacks.comNeo Ivy Capital Management Buys Shares of 209,577 Summit Therapeutics Inc. (NASDAQ:SMMT)May 25, 2025 | marketbeat.com3 High-Flying Stocks That Could Soar Even MoreMay 24, 2025 | fool.comTema Etfs LLC Purchases New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)May 20, 2025 | marketbeat.comRafferty Asset Management LLC Has $5.56 Million Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)May 20, 2025 | marketbeat.comDeutsche Bank AG Has $8.55 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)May 19, 2025 | marketbeat.comGot $100? 3 Top Growth Stocks to Buy That Could Double Your MoneyMay 18, 2025 | fool.comJefferies Financial Group Inc. Acquires Shares of 45,001 Summit Therapeutics Inc. (NASDAQ:SMMT)May 18, 2025 | marketbeat.comNorthern Trust Corp Has $15.55 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)May 17, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)May 16, 2025 | marketbeat.comStockNews.com Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"May 15, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $8.80 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)May 14, 2025 | marketbeat.comHsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)May 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Strong-Buy" at TD CowenMay 12, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Buy" from AnalystsMay 12, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Balyasny Asset Management L.P.May 12, 2025 | marketbeat.comSummit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTCT, SMMT, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$21.30 +0.11 (+0.50%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.PTC Therapeutics NASDAQ:PTCT$48.82 +1.54 (+3.26%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Dr. Reddy's Laboratories NYSE:RDY$14.72 +0.17 (+1.13%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$26.54 +0.51 (+1.94%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
